Vera Therapeutics, Inc. Class A (VERA)

Vera Therapeutics' stock has increased by 44.82% in the past six months but has decreased by 28.5% since the start of the year. Key events include the FDA's Priority Review for atacicept, Q1 2026 financial results showing a wider net loss due to increased spending, Q4 2025 financial results reporting a net loss, an analyst rating downgrade due to competition, insider stock sales, and equity awards to new employees.

As a clinical-stage biotechnology company, Vera Therapeutics, Inc. does not currently have commercially approved products generating revenue. Therefore, traditional demand seasonality for products and services is not applicable to the company at this stage. Its focus is on the research, development, and regulatory approval of its drug candidates. The company's financial performance is primarily driven by its R&D expenses and progress in clinical trials, rather than seasonal fluctuations in product demand.

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing treatments for immunological diseases. Their primary product candidate is atacicept, a fusion protein being evaluated for IgAN and lupus nephritis, with a BLA for atacicept in IgAN under Priority Review by the FDA. The company is also developing MAU868 for BK virus infection and VT-109 for B cell-mediated autoimmune diseases. Vera Therapeutics retains all global developmental and commercial rights to atacicept and MAU868.

Vera Therapeutics, Inc. is headquartered in Brisbane, California, United States. The company's corporate office is located at 2000 Sierra Point Parkway, Suite 1200, Brisbane, CA 94005. While the company is based in the U.S., its shareholder base has a significant geographical origin from the United States (84.1%), with other notable percentages from the United Kingdom (8.5%) and Switzerland (4.53%).

Vera Therapeutics generally holds a positive reputation due to the progress of atacicept. The company has a consensus analyst rating of "Moderate Buy" with a potential upside of approximately 120.0% from its current price. Key events contributing to its reputation include positive clinical trial results, FDA Priority Review, and a focus on unmet medical needs. Despite increased competition and widening losses, sentiment remains positive due to strong clinical data for atacicept.

Vera Therapeutics, Inc. has a significant institutional ownership presence. As of May 1, 2026, 231 institutional owners and shareholders hold a total of 73,790,912 shares. Major institutional owners include Avoro Capital Advisors LLC, Price T Rowe Associates Inc /md/, BlackRock, Inc., Deerfield Management Company, L.p., Vanguard Group Inc, Kynam Capital Management, LP, Eversept Partners, LP, Fmr Llc, Deep Track Capital, LP and Sofinnova Investments, Inc. Overall, institutional ownership accounts for 113.3% of the company, while individuals hold 1.2%.